Select a bar in the table to update this content
An unparalleled resource for the characterization of genes and their role in disease biology and drug response. Choose from thousands of cell lines available as part of our catalog.
The same team of cell line engineering scientists who developed our extensive cell line catalog are also available to generate cell lines on your behalf. Using our genome-editing platform, which comprises CRISPR, rAAV, and ZFN technologies, we are able to make almost any genetic alteration required, from simple knockouts or single point mutations to more complex genomic manipulations.
Horizon is your source for unique, next-generation SAGE® animal research models featuring specific gene deletions, insertions, repressions and modifications, as well as the industry's first and only knockout rat model.
Horizon has coupled our isogenic cell line library with our understanding of cancer biology and the tumor microenvironment along with a broad selection of libraries to be able to offer a range of screening approaches and assay conditions suitable to meet the requirements of almost any project.
Screening capabilities include:
Combination therapies are now emerging as the standard of care in indications such as cancer, inflammation, diabetes, and infectious disease. Horizon’s Combination High Throughput Screening platform (cHTS) operates by comparing a drug or other compound with a second at a specific dose to look for synergistic or antagonistic effects. These are seen by either increasing the anti-proliferative or cell killing effect.
Bioproduction cell lines should not be cost prohibitive. Horizon is revolutionizing the production of large molecule therapeutics, providing innovative solutions for all organizations of all sizes. We provide custom engineering of bioproduction cell lines and also offer a range of off the shelf CHO cell lines ready for immediate use.
Looking for a knockout rat or mouse not included in our standard model portfolio? Your Horizon in vivo model development specialist will work with you to design a custom model to your exact specifications, using our CRISPR-Cas9 or Zinc Finger Nuclease technologies, in as few as 5 months.
Heart disease is the leading cause of death and a major cause of disability throughout much of the developed world. In addition to a wide range of environmental risk factors such as high blood pressure, diabetes, as well as lifestyle factors, such as an unhealthy diet and physical inactivity, underlying genetics can put people at a higher risk for developing heart disease.
Several types of cardiovascular diesase have clear associations between genetic markers and an increased risk of premature heart attacks. Examples include familial hypercholesterolemia, pulmonary arterial hypertension and a number of inherited cardiomyopathies. Research is actively underway to identify further genetic markers linked with disease and to find genes that could be targets to help alleviate or counter risk factors.
Horizon is uniquely suited to helping researchers investigate the underlying basis of disease. We translate genomic information into practical drug discovery and diagnostic tools that accurately recreate the specific genetics of real patients that are significant in human disease onset and progression.
Horizon’s gene editing platform confers the ability to rapidly introduce any genetic variation into any endogenous gene loci of any human cell line; thus accurately modeling real patient genotypes.
These disease models take the form of cell lines, which are being used widely in basic and drug discovery research and provide them as tools, use them as the basis of a wide range of services to power drug discovery and development programs, and offer them as reference standards to help ensure that patient diagnostic testing provides accurate results. Our gene editing platform also is used to generate in vivo models to support drug trials, particularly in the preclinical stage.
Daisuke Ekuni. et al. (2014). Occlusal disharmony accelerates the initiation of atherosclerosis in apoE knockout rat, Lipids Health Dis. 2014; 13: 144
Sergio Vaira. et al. (2012). Creation and Preliminary Characterization of a Leptin Knockout Rat, Endocrinology. 2012 November; 153(11): 5622–5628
David McVey et al. (2014). Generation of Isogenic Cell Lines to Study a Single Disease Associated Variant at the 1P13 Cad Risk Locus, Heart 2014;100:A117